Antipsychotic prescribing for behaviours that challenge in children with intellectual disabilities

SUMMARY Antipsychotics are increasingly prescribed to children with intellectual disabilities for behaviours that challenge. In the UK, only risperidone is licensed in this population, solely for short-term treatment of persistent aggression in conduct disorder in children with subaverage intellectual functioning. Yet antipsychotics are prescribed routinely, indefinitely and off-label for behavioural control, despite weak evidence, serious harms and problematic ethical justification. This article argues such prescribing is unjustifiable. At these doses, antipsychotics act mainly by sedation and suppressing the capacity to express distress, desire and objection. In children often unable to consent or report side-effects, and dependent on adults whose interests may differ, this is pharmacological restraint, with poorly monitored cumulative metabolic, neurological and cardiovascular harms. Behaviours that challenge communicate unmet need. Systematic biological assessment often identifies treatable causes; psychosocial interventions and treatment of physical health problems achieve comparable outcomes without adverse effects. The article presents an assessment framework, deprescribing guidance and good practice points that put the child’s interests are paramount.

Authors

Institutions

Publication Details

Journal
BJPsych Advances
Published
2026-11-19
DOI
https://doi.org/10.1192/bja.2026.10266
Primary Topic
Down syndrome and intellectual disability research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antipsychotic prescribing for behaviours that challenge in children with intellectual disabilities

Annie Swanepoel
BJPsych Advances
Down syndrome and intellectual disability research
article

Antipsychotic prescribing for behaviours that challenge in children with intellectual disabilities

Annie Swanepoel
article en

Abstract

SUMMARY Antipsychotics are increasingly prescribed to children with intellectual disabilities for behaviours that challenge. In the UK, only risperidone is licensed in this population, solely for short-term treatment of persistent aggression in conduct disorder in children with subaverage intellectual functioning. Yet antipsychotics are prescribed routinely, indefinitely and off-label for behavioural control, despite weak evidence, serious harms and problematic ethical justification. This article argues such prescribing is unjustifiable. At these doses, antipsychotics act mainly by sedation and suppressing the capacity to express distress, desire and objection. In children often unable to consent or report side-effects, and dependent on adults whose interests may differ, this is pharmacological restraint, with poorly monitored cumulative metabolic, neurological and cardiovascular harms. Behaviours that challenge communicate unmet need. Systematic biological assessment often identifies treatable causes; psychosocial interventions and treatment of physical health problems achieve comparable outcomes without adverse effects. The article presents an assessment framework, deprescribing guidance and good practice points that put the child’s interests are paramount.

BJPsych Advances
North East London NHS Foundation Trust (GB)
Down syndrome and intellectual disability research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon